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Pleasanton, CA) in September 2012 because of refractory heartIntroduction
The increasing complexity and duration of electrophysiology
procedures have led to the development of alternative
methods of mapping and ablation. One recent technological
advance is the MediGuide Positioning System (St. Jude
Medical, St. Paul, MN). This system superimposes electro-
magnetic ﬁeld tracking over prerecorded ﬂuoroscopic cine
loops, with dynamic compensation for respiratory and
cardiac motion. This system facilitates real-time navigation
while reducing the need for additional ﬂuoroscopy.1–2
Left ventricular assist devices (LVADs) are increasingly
implanted for patients with end-stage heart failure, to
improve survival and functional status. Unfortunately, they
have been reported to produce electromagnetic noise sufﬁ-
cient to result in signiﬁcant device–device interactions.3–6
Despite increasing experience with MediGuide, the potential
for electromagnetic noise from the LVAD to interfere with
normal functioning of the catheter-tracking system is
unknown. We hereby report our successful experience using
the MediGuide technology during an atrial ﬂutter ablation
procedure in a patient with and LVAD implant.
Case report
A 69-year-old man with severe nonischemic cardiomyopathy
(left ventricular ejection fraction 15%) underwent implanta-
tion of an LVAD (HeartMate II; Thoratec Corporation,KEYWORDS Left ventricular assist device; HeartMate II; Atrial ﬂutter;
Catheter ablation; MediGuide
ABBREVIATIONS bpm ¼ beats per minute; CS ¼ coronary sinus; LVAD ¼
left ventricular assist device (Heart Rhythm Case Reports 2015;1:290–292)
Conﬂict of interest: L.M. reports receiving lecture fees from St. Jude
Medical, Biosense Webster, Bristol Myers Squibb, and Pﬁzer and grant
support from St. Jude Medical and Biosense Webster. J.A. reports receiving
lecture fees from Medtronic, Bayer, and Biosense Webster; consulting fees
fromMedtronic, Bayer, and Biotronik; and grant support fromMedtronic. B.
T. reports receiving lecture fees from Medtronic, St. Jude Medical, and
Bayer. P.K. reports receiving consulting fees from Boehringer Ingelheim
and grant support from Boehringer Ingelheim, Actelion, Bayer, Medtronic,
and St. Jude Medical. H.K.N.T. and K.D. report no conﬂicts of interest.
Address reprint requests and correspondence: Dr. Laurent Macle,
Electrophysiology Service, Montreal Heart Institute, 5000 Belanger Street,
Montreal, QC H1T 1C8, Canada. E-mail address: lmacle@mac.com.
2214-0271 B 2015 Heart Rhythm Society. Published by Elsevier Inc. This is an o
(http://creativecommons.org/licenses/by-nc-nd/4.0/).failure symptomatology unresponsive to maximal medical and
cardiac resynchronization therapy (Figure 1). Although this
resulted in initial symptomatic improvement, he represented in
February 2013 with acute decompensated heart failure due to
rapid atrial ﬂutter (Figure 2). Despite therapy with carvedilol at
maximum tolerated doses, his ventricular response remained
uncontrolled at 95–110 beats per minute (bpm) at rest. The
situation was discussed with the heart-failure and cardiac-
transplant team, and a decision was made to proceed with
cavotricuspid isthmus ablation for the treatment of the typical
atrial ﬂutter, in an effort to restore atrioventricular synchrony.
Given the patient’s ongoing ﬂutter, the procedure was
performed under therapeutic oral anticoagulation with warfarin
(international normalized ratio 2.30). A preprocedural trans-
esophageal echocardiogram excluded intracardiac thrombus.
Oxygen saturation and invasive hemodynamic parameters
were continuously monitored throughout the electrophysiol-
ogy procedure. In addition, a cardiac perfusionist continuously
monitored the HeartMate II parameters (pump speed 8400
rpm, pump ﬂow 4.1 L/min, pulse index 5.1, pump power 5.1
W) to ensure there was no device dysfunction related to either
radiofrequency ablation or MediGuide use.
The ablation procedure was undertaken via 2 femoral
venous punctures. Through a 7-French (F) sheath, a
MediGuide-enabled Livewire steerable decapolar diagnostic
catheter (St. Jude Medical) was placed on the lateral wall of the
right atrium as an intracardiac reference (cannulation of the
coronary sinus [CS] was avoided in order to prevent disloca-
tion of the CS lead). Through a steerable 8.5F introducer
(Agilis; St. Jude Medical) a MediGuide-enabled 4-mm bidirec-
tional irrigated radiofrequency ablation catheter (Saﬁre BLU
Duo; St. Jude Medical) was advanced into the right atrium.
Two short ﬂuoroscopic loops (3 seconds) of the heart were then
recorded in posteroanterior and left anterior oblique views.
Those prerecorded electrocardiograph-gated ﬂuoroscopy cine
loops were simultaneously displayed, allowing biplanar real-
time tracking of the CS and ablation catheter tips within the
cine loops. Live ﬂuoroscopy was performed as needed. Typical
counterclockwise right atrial ﬂutter was demonstrated by
activation mapping along the atrial lateral and septal walls.pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.03.008
KEY TEACHING POINTS
 In rare cases, the electromagnetic noise generated
by a left ventricular assist device has been reported
to result in signiﬁcant device–device interactions.
 Our ﬁndings suggest that catheter ablation using
MediGuide technology can be performed in patients
implanted with a HeartMate II left ventricular
assist device.
 Whether MediGuide technology is useful in
reducing radiation exposure during complex
catheter-ablation procedures in patients implanted
with a HeartMate II device remains unknown.
291Nguyen Thanh et al Flutter Ablation Using MediGuide in a HeartMate II PatientCavotricuspid isthmus ablation was performed during ﬂutter
(temperature 481C, power 35 W, ﬂow rate 17 mL/min), and it
resulted in slowing of the tachycardia cycle length, followed by
abrupt termination. Postablation bidirectional block was con-
ﬁrmed using differential pacing from the lateral and the septal
aspects of the ablation line. Total procedural and ﬂuoroscopy
times were 1 hour 16 minutes and 14 minutes respectively. The
procedure was well tolerated, and the patient was discharged 6
days post procedure.Figure 1 A chest X-ray image of the patient implanted with a
biventricular deﬁbrillator (upper arrow), and HeartMate II left ventricular
assist device (lower arrow).Discussion
Herein we have discussed the ﬁrst experience with
MediGuide-assisted ablation in a patient implanted with a
HeartMate II LVAD. The HeartMate II is a continuous-ﬂow
LVAD. It consists of an electric motor that operates by
creating a magnetic ﬁeld that spins a permanent magnet
located within the rotor. The subsequent rotary motion
(usually 7000–10,000 rpm) pumps blood.
Unfortunately, electromagnetic interference emanating
from the LVAD is known to occasionally severely impair
telemetry communication between certain deﬁbrillators and
their programmers.3–6 Speciﬁcally, the electromagnetic sig-
nal generated by the HeartMate II pulse width modulator,
which serve to regulate voltage input to the LVAD motor,
operate at the 7.2-kHz frequency and can interfere with the 8-
kHz operating frequency of the deﬁbrillator telemetry wand.
This problem has been reported with both St. Jude Medical
and Sorin Group (Milan, Italy) devices.3–6
The MediGuide Positioning System consists of 3 compo-
nents: a transmitter generating a 3-dimensional electromag-
netic ﬁeld, an electromagnetic ﬁeld reference sensor attached
to the patient chest, and a miniaturized coil sensor assembled
within the electrophysiology catheters. The MediGuide
transmitter produces a set of magnetic ﬁelds in a range of
frequencies between 10 and 15 kHz, with a magnitude of up
to 200 mT. This transmitter is mounted on the ﬂuoroscopy
detector, aligning the 3-dimensional electromagnetic ﬁeld
with the ﬂuoroscopy ﬁeld. The reference sensor provides
information about the spatial relationship between the chest
wall and the ﬂuoroscopy detector and allows accuratecompensation for respiratory and patient movement. The
sensor-tip catheter is tracked nonﬂuoroscopically within the
3-dimensional electromagnetic ﬁeld and projected onto the
prerecorded cine loops. Prerecorded ﬂuoroscopy cine loop
speed is gated to real-time electrocardiograph cycle length.
Additionally, this information can be incorporated in a 3-
dimensional electroanatomic mapping system to contribute
to the creation and stabilization of cardiac geometry images.
The use of MediGuide technology enhances catheter track-
ing while reducing of radiation exposure during electro-
physiology procedures.2,11
Our concern was the possible interaction between the
HeartMate II and the MediGuide Positioning System, which
could lead to a compromise in HeartMate II function or the
functioning or accuracy of the MediGuide nonﬂuoroscopic
navigation system. Fortunately, despite similar operating
frequencies and operation near the electromagnetic ﬁeld
reference sensor, we noted no adverse impact with the use of
MediGuide navigation system on the LVAD parameters.
Similarly, there was no interference of the HeartMate II
pump on the magnetic ﬁeld with the ability to accurately
track the MediGuide catheter tip (Figure 3), nor with the
quality of electrograms observed on the ablation catheter.
This ﬁnding is consistent with previous reports that have
suggested no signiﬁcant electromagnetic interference
between the HeartMate II device and radiofrequency deliv-
ery; electroanatomic mapping with the CARTO system,
which generates a magnetic ﬁeld of 2.5–65 mT at frequencies
of 2, 2.2, and 3 kHz (Biosense Webster; Johnson & Johnson,
New Brunswick, NJ), or EnSite NAVx system (frequency
5.7 kHz; St. Jude Medical).7–10
Although the use of the MediGuide 3-dimensional cathe-
ter-tracking system was safe and feasible in this case, the
primary objectives of ﬂuoroscopy- and procedure-time reduc-
tion were not achieved. This result was due to the need for
intermittent ﬂuoroscopic imaging in order not to damage or
Figure 2 A twelve-lead electrocardiogram demonstrating typical counterclockwise atrial ﬂutter.
Heart Rhythm Case Reports, Vol 1, No 5, September 2015292dislodge the pacing and deﬁbrillator leads. Moreover, it would
be anticipated that the MediGuide system would be less useful
for left-sided procedures in patients with continuous-ﬂow
LVADs, because of the compressed chambers and presence of
inﬂow cannula requiring close ﬂuoroscopic surveillance.Conclusion
This case report suggests MediGuide technology can be
safely used in the presence of an LVAD. The number of
patients with ventricular assistance devices is growing, and
among them the prevalence of atrial and ventricular arrhyth-
mias is high. Catheter ablation can be an effective and safe
treatment option for such patients. Whether the MediGuide
technology is useful in this population to reduce radiationFigure 3 A ﬂuoroscopy image conﬁrming accurate tracking of the
MediGuide-enabled catheter tip during the ﬂutter ablation procedure.
CR = cranial; LAO = left anterior oblique; SID = source to image distance.exposure during complex catheter-ablation procedures needs
to be studied.
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